Rate of hospitalization due to COVID-19 and death reduced for treated versus untreated patients among those aged 65 years and older
Metformin, Ivermectin, Fluvoxamine Do Not Prevent Severe COVID-19
No difference in the primary end point seen with any of the three medications versus placebo among adults with overweight or obesity
Dupilumab Studied in Patients Hospitalized for COVID-19
No difference seen between dupilumab and placebo groups in adverse events or primary outcome of ventilator-free survival at 28 days
Survival Benefit With Triple Therapy for Severe COVID-19
Compared with dual therapy, significant survival benefit seen with dexamethasone, remdesivir, and baricitinib but no change in length of stay
Survival Benefit Seen With Triple Therapy for Severe COVID-19
Compared with dual therapy, significant survival benefit seen with dexamethasone, remdesivir, and baricitinib but no change in length of stay
WHO Guideline Advises Against Fluvoxamine, Colchicine for COVID-19
For nonsevere COVID-19, 11th version of living guideline recommends against fluvoxamine (except in context of clinical trial), colchicine
Asthma Drug Fluticasone Fails as Potential COVID-19 Treatment
Finding from a nationwide study of 5,000 participants that continues to evaluate existing drugs to treat mild-to-moderate COVID-19
Modest Increase Seen in Methadone-Involved OD Deaths in March 2020
Increase in methadone-involved deaths in March 2020 not thought to be tied to expanded opioid treatment program take-home policies
FDA Allows Pharmacists to Prescribe COVID-19 Drug Paxlovid
However, patients who test positive for COVID-19 should still consider reaching out to their regular health care provider for Paxlovid first
Severe COVID-19 Rates Low With Monoclonal Antibody Therapy During Delta Surge
Rates of severe disease low for high-risk patients with mild-to-moderate COVID-19 treated with antispike monoclonal antibodies